Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer

被引：36
作者：
Di Bartolomeo, Maria [1 ]
Pietrantonio, Filippo [1 ]
Pellegrinelli, Alessandro [2 ]
Martinetti, Antonia [1 ]
Mariani, Luigi [3 ]
Daidone, Maria Grazia [4 ]
Bajetta, Emilio [5 ]
Pelosi, Giuseppe [2 ]
de Braud, Filippo [1 ]
Floriani, Irene [6 ]
Miceli, Rosalba
机构：
[1] Fdn IRCCS, Ist Nazl Tumori, Dept Med Oncol, Via Venezian 1, I-20133 Milan, Italy
[2] Fdn IRCCS, Ist Nazl Tumori, Dept Pathol, Via Venezian 1, I-20133 Milan, Italy
[3] Fdn IRCCS, Ist Nazl Tumori, Unit Med Stat Biometry & Bioinformat, Via Venezian 1, I-20133 Milan, Italy
[4] Fdn IRCCS, Ist Nazl Tumori, Expt Oncol & Mol Med Dept, Via Venezian 1, I-20133 Milan, Italy
[5] IDO Policlin, Med Oncol Unit, Monza, Italy
[6] IRCCS, Ist Ric Farmacol Mario Negri, Milan, Italy
来源：
GASTRIC CANCER | 2016年 / 19卷 / 02期
关键词：
Osteopontin; Gastric cancer; Prognosis; Biomarker; Adjuvant chemotherapy; ADJUVANT CHEMOTHERAPY; SURVIVAL; CARCINOMA; CLASSIFICATION; METAANALYSIS; METASTASIS; VALIDATION; SURROGATE; INVASION; SURGERY;
D O I：
10.1007/s10120-015-0495-y
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A correlation between osteopontin, E-cadherin, beta-catenin, and cyclooxygenase 2 overexpression and poor clinicopathological features and prognosis has been previously suggested in gastric cancer. This translational study was aimed at assessing the correlation of these immunohistochemical biomarkers with outcome in patients with radically resected gastric cancer. We analyzed osteopontin, E-cadherin, beta-catenin, and cyclooxygenase 2 expression by immunohistochemistry in 346 primary gastric tumor tissue samples from patients enrolled in the ITACA-S trial. This phase III study randomized patients with radically resected gastric cancer to receive adjuvant chemotherapy with either 5-fluorouracil and leucovorin or a sequential regimen of infusional 5-fluorouracil and leucovorin plus irinotecan followed by cisplatin and docetaxel. High expression of osteopontin was correlated with high histological grade, diffuse histotype, and peritoneal relapse, but not with TNM stage. Moreover, osteopontin overexpression was associated with higher risk of tumor recurrence and metastases, and was an independent prognostic factor for both relapse-free and overall survival of gastric cancer patients following adjuvant chemotherapy. Abnormal E-cadherin expression and abnormal beta-catenin expression were correlated with more advanced disease stage, and as a consequence, with poor outcome. Our results suggest that osteopontin overexpression is a valuable independent predictor of tumor recurrence and survival in patients with radically resected gastric cancer.
引用
收藏
页码：412 / 420
页数：9
相关论文
共 26 条
[1]   Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer [J].
Bajetta, E. ;
Floriani, I. ;
Di Bartolomeo, M. ;
Labianca, R. ;
Falcone, A. ;
Di Costanzo, F. ;
Comella, G. ;
Amadori, D. ;
Pinto, C. ;
Carlomagno, C. ;
Nitti, D. ;
Daniele, B. ;
Mini, E. ;
Poli, D. ;
Santoro, A. ;
Mosconi, S. ;
Casaretti, R. ;
Boni, C. ;
Pinotti, G. ;
Bidoli, P. ;
Landi, L. ;
Rosati, G. ;
Ravaioli, A. ;
Cantore, M. ;
Di Fabio, F. ;
Aitini, E. ;
Marchet, A. .
ANNALS OF ONCOLOGY, 2014, 25 (07) :1373-1378
[2]   Biomarkers and surrogate end points-the challenge of statistical validation [J].
Buyse, Marc ;
Sargent, Daniel J. ;
Grothey, Axel ;
Matheson, Alastair ;
De Gramont, Aimery .
NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (06) :309-317
[3]   Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers [J].
Cao, Dong-Xing ;
Li, Zhi-Jie ;
Jiang, Xiao-Ou ;
Lum, Yick Liang ;
Khin, Ester ;
Lee, Nikki P. ;
Wu, Guo-Hao ;
Luk, John M. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (30) :3923-3930
[4]   Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data [J].
Chou, I ;
Norman, AR ;
Cunningham, D ;
Waters, JS ;
Oates, J ;
Ross, PJ .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) :2395-2403
[5]   Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer [J].
Cunningham, David ;
Allum, William H. ;
Stenning, Sally P. ;
Thompson, Jeremy N. ;
Van de Velde, Cornelis J. H. ;
Nicolson, Marianne ;
Scarffe, J. Howard ;
Lofts, Fiona J. ;
Falk, Stephen J. ;
Iveson, Timothy J. ;
Smith, David B. ;
Langley, Ruth E. ;
Verma, Monica ;
Weeden, Simon ;
Chua, Yu Jo .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (01) :11-20
[6]   Protein expression of osteopontin in tumor tissues is an independent prognostic indicator in gastric cancer [J].
Dai, Ni ;
Bao, Quan ;
Lu, Aiping ;
Li, Jiyou .
ONCOLOGY, 2007, 72 (1-2) :89-96
[7]   Prognostic significance of osteopontin expression in human gastric carcinoma [J].
Higashiyama, Motoshige ;
Ito, Tetsuo ;
Tanaka, Eiji ;
Shimada, Yutaka .
ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (12) :3419-3427
[8]   Immunohistochemical Expression of Osteopontin in Gastric Cancer [J].
Imano, Motohiro ;
Satou, Takao ;
Itoh, Tatsuki ;
Sakai, Kenichi ;
Ishimaru, Eizaburo ;
Yasuda, Atsushi ;
Peng, Ying-Feng ;
Shinkai, Masayuki ;
Akai, Fumiharu ;
Yasuda, Takushi ;
Imamoto, Haruhiko ;
Okuno, Kiyokata ;
Ito, Hiroyuki ;
Shiozaki, Hitoshi ;
Ohyanagi, Harumasa .
JOURNAL OF GASTROINTESTINAL SURGERY, 2009, 13 (09) :1577-1582
[9]   An inducible short-hairpin RNA vector against osteopontin reduces metastatic potential of human esophageal squamous cell carcinoma in vitro and in vivo [J].
Ito, T ;
Hashimoto, Y ;
Tanaka, E ;
Kan, T ;
Tsunoda, S ;
Sato, F ;
Higashiyama, M ;
Okumura, T ;
Shimada, Y .
CLINICAL CANCER RESEARCH, 2006, 12 (04) :1308-1316
[10]   Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: Relationship with patient survival [J].
Jawhari, A ;
Jordan, S ;
Poole, S ;
Browne, P ;
Pignatelli, M ;
Farthing, MJG .
GASTROENTEROLOGY, 1997, 112 (01) :46-54
123